More than half of department chairs at U.S. medical schools and teaching hospitals have financial ties with the drug industry, a new study finds. There is not a single aspect of medicine in which the drug companies do not have substantial and deep relationships, [including] doctors-in-training, resident physicians, researchers, physicians-in-practice, the people who review drugs for the federal government and the people who review studies," said lead researcher Eric Campbell, associate professor at the Institute for Health Policy at Massachusetts General Hospital and Harvard Medical School in Boston. "Drug companies have relationships with everyone," he continued. "They're involved in every aspect of medicine. Someone has to decide which of these is OK." The study, the first to examine the extent of these institutional relationships, is published in the Oct. 17 issue of the Journal of the American Medical Association. "I think the paper is a very valuable contribution, in that it provides what's probably the first comprehensive documentation of the extent of relationships that involve department chairs, and department chairs are certainly the key agents of overseeing and maintaining the day-to-day operations of a medical school or teaching hospital," said Dr. David Korn ... at the Association of American Medical Colleges in Washington, D.C. The issue of medicine's ties to industry has been a hot one of late. One study found that third-year medical students get, on average, one gift or attend one activity sponsored by a drug maker each week. "Now it's up to the policymakers and people who run medical schools," said Campbell. "They need to come up with some rules and they need to be new rules. I believe there's very little reasonable justification for why drug companies should be involved in the education of medical students."